The authors further demonstrated that G6PDH overexpression induces MCF-7 breast cancer cell resistance to lapatinib [182], a tyrosine kinase inhibitor used in the treatment of patients with breast cancer [184]. This evidence concerns the gene H6PD and breast carcinoma.